ALK and non-small cell lung carcinoma: Here, we report an extended series of 15 consecutive relapsed NSCLC patients (12 ALK+, 3 ROS1+) treated at our center that were investigated by liquid biopsy at TKI failure, through amplicon deep sequencing of the ALK/ROS1 kinase domains.